

OHMR Research Ethics and Governance Metrics Program



Metrics Activity Report for NSW PHOs

Reporting Period: Quarter 3 2023
01/07/2023 – 30/09/2023

NSW Office for Health and Medical Research

Executive Summary

This report includes strategic and site level performance and compliance metrics that are collected by the Office for Health and Medical Research (OHMR) from NSW Public Health Organisations (PHOs) on studies authorised during the reporting period. The performance of NSW PHOs on health and medical research are reported four times a year, each covering a 3-month period.

Overall Performance Environment

REGIS is the online platform used to manage ethics and governance applications for all NSW Public Health Organisations. OHMR has undertaken data validation activities with LHD Research Office staff to accurately represent research ethics and governance performance on this platform. These rolling validation activities may result in data reported here to differ from previous reports.

Update to Metrics Program

As reported previously, OHMR implemented the following changes to the Research Key Performance Indicators (KPIs) for inclusion in the Chief Executives' Services Agreement:

- Change benchmark to/measure/Total Time/rather than time spent with LHD Research Office alone
- Number of Greater than Low Risk projects (GLR) processed within application total time
 - 90 days for ethics, 60 days for governance
 - Threshold changes
 - >75% = Performing
 - 55%-75% = Underperforming
 - <55% = Not performing



Ethics Review Timelines of Human Research in NSW PHOs

KPI21-03: Ethics Application Approvals - By the Human Research Ethics Committee (HREC) within 90 calendar days

NSW State Benchmark: The benchmark for the 2021/22 financial year onwards is for reviewing human research studies by NSW PHO HRECs within 90 calendar days

Definition:

The proportion of Ethics applications (excluding LNR) approved by the HREC within 90 calendar days, approved within the reporting period.

Context:

The measure will no longer account for clock stops in accordance with the NHMRC Certification Handbook. Instead, the end-to-end time will be measured. Where a valid application is received, the clock starts on the submission closing date for the HREC meeting at which an application will be reviewed. The clock is stopped when the HREC formally notifies the applicant of the final decision.

Desired Outcome:

Ensuring timely processing of ethics approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.

Selection Criteria Summary:

Scope	Human Research Ethics Applications
Frequency	Quarterly
Inclusions	<ul style="list-style-type: none"> Study Type = All Application Type = Greater than low risk Approval Type = Approved/ Approved with conditions within the reporting period
Exclusions	<ul style="list-style-type: none"> Application Type = Low and negligible risk Approval Type = Not within the reporting period Migrated studies
Total	Total time is defined as the measurement of the total, unadjusted time from the Submission Closing Date of the first meeting the application is assigned to, to when the final decision notification email is sent.

Summary for Metric 3

Ethics review performance of NSW HRECs according to the < **90-day benchmark** for studies approved during the reporting period (**Quarter 3 2023**) are shown in **Table 1**.

During the reporting period, 234 studies (greater than low risk pathway) were approved by a NSW Health HREC with an average review time (total time) of 48 days. Of these 234 studies, 93 (40%) were classified as clinical trials (**Table 2**).

Further breakdown of clinical trial approvals by sponsor type is provided in **Table 3** (by NSW PHOs) and **Table 4** (by quarter). Historical performance of NSW PHOs against the old and new benchmarks for the review and approval of human research ethics applications is presented in **Table 5**.

Table 1. The **90 calendar days benchmark** for approval of human research ethics applications (**greater than low risk**) during the reporting period.

NSW PHOs	Ethics Approval (Q3 2023)					
	All greater than low risk applications					
	Total Number of Applications	Total Time 90 Day Benchmark			Total Time Breakdown (calendar days)	
		Count < 90 Day Benchmark	% < 90 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Researcher Time
BLLBRRY	27	24	89%	47	29	18
CINSW	5	5	100%	49	35	15
HNELHD	22	22	100%	30	16	14
ISLHD	5	5	100%	54	36	18
JHFMHN	1	1	100%	88	38	50
NBMLHD	3	1	33%	93	70	23
NNSWLHD	2	2	100%	48	42	7
NSLHD	31	31	100%	40	26	14
SCHN	22	22	100%	46	28	18
SESLHD	10	7	70%	73	54	20
SLHD-CCD	6	6	100%	52	23	29
SLHD-RPA	44	44	100%	33	16	17
SVHN	16	13	81%	55	26	29
SWSLHD	12	10	83%	53	39	13
WNSWLHD	4	4	100%	69	47	22
WSLHD	24	21	88%	70	44	26
TOTAL	234	218	93%	48	29	19

Table 2. The 90 calendar days benchmark for the approval of **clinical trials** (greater than low risk) during the **reporting period**.

NSW PHOs	Ethics Approval (Q3 2023)					
	Clinical Trials					
	Total Number of Applications	Total Time 90 Day Benchmark			Total Time Breakdown (calendar days)	
		Count < 90 Day Benchmark	% < 90 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Researcher Time
BLLBRRY	27	24	89%	47	29	18
CINSW	0	0	-	-	-	-
HNELHD	10	10	100%	30	18	13
ISLHD	0	0	-	-	-	-
JHFMHN	0	0	-	-	-	-
NBMLHD	2	1	50%	89	62	28
NNSWLHD	0	0	-	-	-	-
NSLHD	7	7	100%	45	27	18
SCHN	11	11	100%	40	25	15
SESLHD	2	1	50%	91	72	20
SLHD-CCD	2	2	100%	54	23	31
SLHD-RPA	12	12	100%	34	19	15
SVHN	7	5	71%	73	32	41
SWSLHD	5	5	100%	50	30	20
WNSWLHD	0	0	-	-	-	-
WSLHD	8	7	88%	74	47	27
TOTAL	93	85	91%	49	29	20

Table 3. Breakdown of NSW PHO performances in **clinical trial approvals** (greater than low risk) during the reporting period **by sponsor type**

	Collaborative group			Commercial entity			Investigator-initiated		
NSW PHOs	Total # of Applications	Average	Average	Total # of Applications	Average	Average	Total # of Applications	Average	Average
		Research Office Time (days)	Total Time (days)		Research Office Time (days)	Total Time (days)		Research Office Time (days)	Total Time (days)
BLLBRRY	1	112	205	25	24	35	1	59	194
CINSW	0	-	-	0	-	-	0	-	-
HNELHD	3	22	50	1	15	15	6	16	23
ISLHD	0	-	-	0	-	-	0	-	-
JHFMHN	0	-	-	0	-	-	0	-	-
NBMLHD	0	-	-	2	62	89	0	-	-
NNSWLHD	0	-	-	0	-	-	0	-	-
NSLHD	3	17	31	0	-	-	4	34	55
SCHN	3	17	22	6	28	47	2	31	47
SESLHD	1	88	118	1	55	64	0	-	-
SLHD-CCD	0	-	-	0	-	-	2	23	54
SLHD-RPA	5	16	26	0	-	-	7	21	40
SVHN	1	32	58	4	34	88	2	27	49
SWSLHD	0	-	-	3	32	57	2	28	40
WNSWLHD	0	-	-	0	-	-	0	-	-
WSLHD	1	68	97	6	42	68	1	60	89
Grand Total	18	31	51	48	30	49	27	27	48

Table 4. Quarterly **clinical trial approvals** (greater than low risk) in the last 3 reporting period (between 01/01/2023 and 30/09/2023), **by sponsor type**

	Q1 2023			Q2 2023			Q3 2023		
Sponsor Type	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
Collaborative Group	11	39	89	10	37	72	18	31	51
Commercial Entity	45	42	58	46	33	56	48	30	49
Investigator Initiated	23	31	69	32	32	57	27	27	48
Total	79	37	65	88	33	58	93	29	49

Table 5. Historical performance of NSW PHOs against **the old and new benchmarks** for the review and approval of human research ethics applications (greater than low risk) in the last 3 reporting period (between 01/01/2023 and 30/09/2023).

NSW PHOs		Q1 2023							Q2 2023							Q3 2023						
		Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)			Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)			Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)		
			Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)
BLLBRRY	23	20	87%	19	22	96%	44	21	20	95%	22	20	95%	48	27	25	93%	18	24	89%	47	
CINSW	3	3	100%	21	2	67%	66	8	6	75%	28	6	75%	77	5	5	100%	15	5	100%	49	
HNELHD	32	30	94%	22	32	100%	37	29	29	100%	14	29	100%	31	22	21	95%	14	22	100%	30	
ISLHD	0	0	-	-	0	-	-	3	3	100%	27	3	100%	67	5	5	100%	18	5	100%	54	
JHFMHN	3	3	100%	38	3	100%	73	4	4	100%	3	4	100%	46	1	0	0%	50	1	100%	88	
NBMLHD	4	4	100%	20	4	100%	71	3	2	67%	35	3	100%	76	3	3	100%	23	1	33%	93	
NNSWLHD	3	2	67%	32	2	67%	53	2	2	100%	32	1	50%	86	2	2	100%	7	2	100%	48	
NSLHD	14	9	64%	54	4	29%	122	31	27	87%	20	27	87%	52	31	31	100%	14	31	100%	40	
SCHN	11	9	82%	25	10	91%	62	12	11	92%	27	12	100%	59	22	21	95%	18	22	100%	46	
SESLHD	22	19	86%	26	20	91%	70	13	13	100%	15	13	100%	64	10	9	90%	20	7	70%	73	
SLHD-CCD	5	3	60%	44	5	100%	63	7	5	71%	32	7	100%	57	6	5	83%	29	6	100%	52	
SLHD-RPA	33	24	73%	33	32	97%	53	53	53	100%	18	53	100%	37	44	42	95%	17	44	100%	33	
SVHN	28	21	75%	41	21	75%	78	13	8	62%	37	11	85%	65	16	12	75%	29	13	81%	55	
SWSLHD	20	18	90%	20	17	85%	54	14	13	93%	19	12	86%	57	12	12	100%	13	10	83%	53	
WNSWLHD	4	2	50%	214	2	50%	272	5	5	100%	12	5	100%	39	4	4	100%	22	4	100%	69	
WSLHD	20	16	80%	25	20	100%	64	27	21	78%	26	20	74%	75	24	22	92%	26	21	88%	70	
TOTAL	225	183	81%	32	196	87%	65	245	222	91%	21	226	92%	52	234	219	94%	19	218	93%	48	



Site-specific Assessment (SSA) Authorisation Timelines of Human Research Projects in NSW PHOs

KPI21-04: Research Governance Application Authorisations – SSA Authorisations within 60 calendar days

NSW State Benchmark: The benchmark for the 2021/22 financial year onwards for authorisation of SSA applications is 60 calendar days

Definition:

The proportion of site-specific assessment (SSA) applications (excluding lower to negligible risk) authorised by the Research Governance Office (RGO) within 60 calendar days, authorised within the reporting period.

Context:

The measure will no longer account for clock stops in accordance with the National Health and Medical Research Council Certification. Handbook. Instead, the end-to-end time will be measured. The SSA application received date is the date the RGO or designee receives an SSA application from a researcher regardless of whether it is complete and/or deemed valid. The clock is stopped when the final SSA decision letter is provided to the site principal investigator.

Desired Outcome:

Ensuring timely processing of site approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.

Selection Criteria Summary:

Scope	Site-specific assessment (SSA) applications
Frequency	Quarterly
Inclusions	<ul style="list-style-type: none"> Study Type = All Application Type = Greater than low risk Approval Type = “Authorised” or “authorised with conditions” within the reporting period
Exclusions	<ul style="list-style-type: none"> Application Type = Low and negligible risk Migrated studies

Total Time:

Total time is the measurement of the total, unadjusted time from the Submission Date to when the final decision notification email is sent granting approval.

Summary:

SSA review performance of NSW PHOs according to the **<60-day benchmark** for studies authorised during the reporting period (**Quarter 3 2023**) are shown in **Table 6**. During the reporting period,

461 studies (greater than low risk pathway) were authorised in NSW PHOs with an average review time (total time) of **36** days.

Of these **461** studies, 228 were classified as clinical trials (**Table 7**).

Further breakdown of clinical trial SSA authorisations by sponsor type is provided in **Table 8** (by NSW PHOs) and **Table 9** (by quarter). Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of governance applications is presented in **Table 10**.

Table 6: The 60 calendar days benchmark for authorisation of governance applications (greater than low risk) during the reporting period.

NSW PHOs	SSA Approvals (Q3 2023)							
	All greater than low risk applications							
		60 Day Benchmark (without clock)			Total Time Breakdown (calendar days)			
	Total Number of Applications	Count of < 60 Day Benchmark	% < 60 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Head of Dept Time	Average Chief Exec Time	Average Researcher Time
ASNSW	3	1	33%	158	64	39	59	55
Calvary	7	7	100%	11	8	2	1	2
CCLHD	11	11	100%	13	5	5	0	4
FWLHD	1	1	100%	11	11	0	0	0
HNELHD	33	33	100%	27	13	5	1	9
ISLHD	17	17	100%	5	2	3	0	0
JHFMHN	2	2	100%	51	46	4	0	1
MLHD	4	4	100%	18	11	5	3	2
MNCLHD	6	6	100%	19	6	10	3	3
NBMLHD	7	7	100%	53	36	8	2	9
NNSWLHD	9	9	100%	22	13	5	3	4
NSLHD	47	44	94%	30	14	6	2	10
NSWHPTH	12	10	83%	61	35	13	1	13
SCHN	21	21	100%	34	9	11	0	14
SESLHD	38	26	68%	49	13	15	0	21
SLHD-CCD	16	16	100%	25	5	10	2	10
SLHD-RPA	60	60	100%	24	6	8	2	9
SNSWLHD	0	0	-	-	-	-	-	-
SVHN	41	28	68%	60	19	8	1	34
SWSLHD	47	39	83%	50	28	11	0	11
WNSWLHD	8	8	100%	11	5	6	0	0
WSLHD	71	63	89%	34	9	9	4	16
TOTAL	461	413	90%	36	14	9	2	13

Table 7: The 60 calendar days benchmark for the authorisation of clinical trials (greater than low risk) during the reporting period.

NSW PHOs	SSA Approvals (Q3 2023) Clinical Trials							
	Total Number of Applications	60 Day Benchmark (without clock)			Total Time Breakdown (calendar days)			
		Count of < 60 Day Benchmark	% < 60 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Head of Dept Time	Average Chief Exec Time	Average Researcher Time
ASNSW	1	0	0	223	154	66	3	3
CALVARY	5	5	100%	11	8	1	2	2
CCLHD	6	6	100%	11	4	6	0	0
FWLHD	0	0	-	-	-	-	-	-
HNELHD	15	15	100%	34	13	8	1	13
ISLHD	8	8	100%	5	1	4	0	0
JHFMHN	1	1	1	53	50	1	0	2
MLHD	1	1	100%	31	15	11	5	5
MNCLHD	2	2	100%	10	2	5	4	4
NBMLHD	4	4	100%	59	37	12	3	10
NNSWLHD	5	5	100%	19	10	4	5	4
NSLHD	17	15	88%	34	15	7	2	13
NSWHPH	0	0	-	-	-	-	-	-
SCHN	11	11	100%	37	10	11	0	17
SESLHD	20	15	75%	44	12	16	0	14
SLHD-CCD	8	8	100%	22	4	13	1	5
SLHD-RPA	24	24	100%	31	7	14	3	10
SNSWLHD	0	0	-	-	-	-	-	-
SVHN	29	20	69%	51	14	8	1	29
SWSLHD	25	20	80%	53	28	12	0	12
WNSWLHD	5	5	100%	14	6	8	0	0
WSLHD	41	38	93%	27	6	8	5	13
TOTAL	228	203	89%	35	12	10	2	13

Table 8. NSW PHO performances in clinical trial authorisations (greater than low risk) during the reporting period, by sponsor type.

	Collaborative group			Commercial entity			Investigator-initiated		
NSW PHOs	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
ASNSW	0	-	-	0	-	-	1	154	223
CALVARY	0	-	-	3	8	10	2	8	13
CCLHD	3	5	9	3	4	13	0	-	-
FWLHD	0	-	-	0	-	-	0	-	-
HNELHD	4	14	38	5	9	20	6	16	44
ISLHD	1	0	2	6	1	5	1	1	5
JHFMHN	0	-	-	0	-	-	0	-	-
MLHD	0	-	-	0	-	-	1	15	31
MNCLHD	1	1	7	1	2	13	0	-	-
NBMLHD	1	29	59	1	24	57	2	48	59
NNSWLHD	1	8	13	3	10	19	1	14	24
NSLHD	5	8	18	4	16	26	8	18	49
NSWHPTH	0	-	-	0	-	-	0	-	-
SCHN	2	11	46	7	6	35	2	21	37
SESLHD	12	12	56	8	13	26	0	-	-
SLHD-CCD	2	3	33	4	2	17	2	8	20
SLHD-RPA	4	12	44	8	7	26	12	5	29
SNSWLHD	0	-	-	0	-	-	0	-	-
SVHN	4	7	61	18	11	39	7	24	76
SWSLHD	4	36	88	16	21	37	5	45	74
WNSWLHD	0	-	-	4	8	17	1	1	2
WSLHD	5	6	25	27	5	29	9	9	24
Total	50	12	43	118	9	28	60	19	44

Table 9. Quarterly clinical trial authorisations (greater than low risk applications) approved during the last 3 reporting period, by sponsor type

	Q1 2023			Q2 2023			Q3 2023		
Sponsor Type	Total # of Applications	Average Research Office	Average Total Time	Total # of Applications	Average Research Office	Average Total Time	Total # of Applications	Average Research Office	Average Total Time
Collaborative Group	42	14	58	41	12	56	50	12	43
Commercial Entity	105	12	34	118	8	28	118	9	28
Investigator Initiated	65	12	50	62	13	60	60	19	44
Total	212	12	43	221	10	42	228	12	35

Table 10. Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of SSA applications (greater than low risk) for the last 3 reporting periods (between 01/01/2023 and 30/09/2023).

	Q1 2023							Q2 2023							Q3 2023						
LHD	Number of Applications	15 Day Benchmark (with clock)			60 Day Benchmark (without clock)			Number of Applications	15 Day Benchmark (without clock)			60 Day Benchmark (without clock)			Number of Applications	15 Day Benchmark (with clock)			60 Day Benchmark (without clock)		
		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)
ASNSW	0	0	-	-	0	-	-	0	0	-	-	0	-	-	3	1	0.3333	64	1	33%	158
CALVARY	9	4	44%	16	7	78%	39	14	13	93%	6	13	93%	18	7	6	86%	8	7	100%	11
CCLHD	8	8	100%	4	8	100%	13	14	13	93%	5	14	100%	12	11	10	91%	5	11	100%	13
FWLHD	1	1	100%	8	1	100%	15	0	0	-	-	0	-	-	1	1	100%	11	1	100%	11
HNELHD	38	26	68%	12	34	89%	36	35	25	71%	10	34	97%	25	33	21	64%	13	33	100%	27
ISLHD	15	15	100%	1	15	100%	3	18	18	100%	1	18	100%	7	17	17	100%	2	17	100%	5
JHFMHN	1	0	0%	28	1	100%	28	2	0	0	29	2	100%	29	2	0	0	46	2	100%	51
MLHD	2	2	100%	3	2	100%	5	1	1	100%	7	0	0%	80	4	3	75%	11	4	100%	18
MNCLHD	8	6	75%	12	8	100%	23	12	10	83%	10	10	83%	42	6	6	100%	6	6	100%	19
NBMLHD	7	1	14%	21	7	100%	42	7	3	43%	20	7	100%	46	7	1	14%	36	7	100%	53
NNSWLHD	6	3	50%	12	6	100%	29	4	3	75%	5	3	75%	33	9	6	67%	13	9	100%	22
NSLHD	29	7	24%	36	16	55%	71	29	20	69%	11	25	86%	40	47	27	57%	14	44	94%	30
NSWHPH	3	2	67%	11	2	67%	70	7	3	43%	19	1	14%	124	12	1	8%	35	10	83%	61
SCHN	18	14	78%	10	9	50%	109	25	22	88%	10	25	100%	38	21	17	81%	9	21	100%	34
SESLHD	51	32	63%	14	39	76%	42	41	33	80%	8	35	85%	42	38	22	58%	13	26	68%	49
SLHD-CCD	22	22	100%	1	22	100%	19	20	19	95%	3	20	100%	29	16	14	88%	5	16	100%	25
SLHD-RPA	67	62	93%	5	67	100%	28	50	49	98%	2	50	100%	22	60	51	85%	6	60	100%	24
SNSWLHD	3	1	33%	27	3	100%	45	1	0	0%	77	0	0%	119	0	0	-	-	0	-	-
SVHN	32	21	66%	11	19	59%	67	39	34	87%	10	28	72%	66	41	32	78%	19	28	68%	60
SWSLHD	43	21	49%	16	33	77%	62	43	1	2%	30	39	91%	62	47	8	17%	28	39	83%	50
WNSWLHD	13	12	92%	5	11	85%	51	5	5	100%	2	4	80%	22	8	8	100%	5	8	100%	11
WSLHD	60	33	55%	16	44	73%	55	66	55	83%	9	56	85%	48	71	63	89%	9	63	89%	34
Total	436	293	67%	13	351	81%	46	433	327	76%	10	384	89%	40	461	315	68%	14	413	90%	36

A list of NSW PHOs names and abbreviations that review and/or authorise human research studies:

Human Research Ethics Committee/ Research Governance Office Names	Abbreviation used in the tables	Ethics	Site
Ambulance Service of NSW	ASNSW		Yes
Bellberry	BLLBRRY	Yes	
Calvary Mater Hospital Newcastle	CALVARY		Yes
Central Coast LHD	CCLHD		Yes
NSW Population & Health Services Research Ethics Committee	CINSW	Yes	
Greater Western LHD	WNSWLHD	Yes	Yes
Hammond Care	HCARE		Yes
Hunter New England LHD	HNELHD	Yes	Yes
Justice Health & Forensic Mental Health Network	JHFMHN	Yes	Yes
Mid North Coast LHD	MNCLHD		Yes
Murrumbidgee LHD	MLHD		Yes
Northern NSW LHD	NNSWLHD	Yes	Yes
Nepean Blue Mountains LHD	NBMLHD	Yes	Yes
Northern Sydney LHD	NSLHD	Yes	Yes
NSW Health Pathology	NSWHPTH		Yes
Royal Rehabilitation Centre Sydney HREC	RRCS	Yes	
Sydney Children's Hospitals Network	SCHN	Yes	Yes
South Eastern Sydney LHD	SESLHD	Yes	Yes
Sydney LHD (Concord Zone)	SLHD – CCD	Yes	Yes
Sydney LHD (RPAH Zone)	SLHD – RPA	Yes	Yes
Southern NSW LHD	SNSWLHD		Yes
St Vincent's Hospital	SVHN	Yes	Yes
South Western Sydney LHD	SWSLHD	Yes	Yes
Illawarra Shoalhaven LHD (joint committee with University of Wollongong)	ISLHD	Yes	Yes
Western Sydney LHD	WSLHD	Yes	Yes



For more information

This report has been prepared by the Research Ethics and Governance Unit in Office for Health and Medical Research.

For further enquiries and for the use of this report please contact:

James Cokayne

Principal Policy Officer

Research Ethics and Governance Unit

Office for Health and Medical Research

[Tel \(02\) 9391 9920](tel:0293919920) | james.cokayne@health.nsw.gov.au

Yagiz Alp Aksoy

Senior Policy Officer

Research Ethics and Governance Unit

Office for Health and Medical Research

[Tel \(02\) 9461 7887](tel:0294617887) | yagiz.aksoy@health.nsw.gov.au

Jackie Nie

Policy Officer and Data Analyst

Research Ethics and Governance Unit

Office for Health and Medical Research

[Tel \(02\) 9391 9854](tel:0293919854) | Jackie.nie@health.nsw.gov.au